Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts
Authors:
- Mj Terrier-LacombeMTMj Terrier-Lacombe
- MC BisseryMBMC Bissery
- Am VénuatAVAm Vénuat
- F GyergyayFGF Gyergyay
- J BénardJBJ Bénard
- J MorizetJMJ Morizet
- I BolandIBI Boland
- P ArdouinPAP Ardouin
- B Bressac-De-PailleretsBBB Bressac-De-Paillerets
- A GouyetteAGA Gouyette
Open Access
- 1 August 1996
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 74 (4) , 537-545
Abstract
The anti-tumour activity of CPT-11, a topoisomerase I inhibitor, was evaluated in four human neural-crest-derived paediatric tumour xenografts; one peripheral primitive neuroectodermal tumour (pPNET) (SK-N-MC) and three neuroblastomas. Two models, SK-N-MC and IGR-N835, were established in athymic mice from a previously established in vitro cell line. Two new neuroblastoma xenograft models, IGR-NB3 and IGR-NB8, were derived from previously untreated non-metastatic neuroblastomas. They exhibited the classic histological features of immature neuroblastoma along with N-myc amplification, paradiploidy, chromosome 1p deletions and overexpression of the human mdr 1 gene. These tumour markers have been shown to be poor prognostic factors in children treated for neuroblastoma. CPT-11 was tested against advanced stage subcutaneous tumours. CPT-11 was administered i.v. using an intermittent (q4d x 3) and a daily x 5 schedule. The optimal dosage and schedule was 40 mg kg-1 daily for 5 days. At this highest non-toxic dose, CPT-11 induced 100% tumour-free survivors on day 121 in mice bearing the pPNET SK-N-MC xenograft. For the three neuroblastoma xenografts, 38-100% complete tumour regressions were observed with a tumour growth delay from 38 to 42 days, and anti-tumour activity was clearly sustained at a lower dosage (27 mg kg-1 day-1). The efficacy of five anti-cancer drugs commonly used in paediatric oncology or in clinical development was evaluated against SK-N-MC and IGR-N835. The sensitivity of these two xenografts to cyclophosphamide, thiotepa and cisplatin was of the same order of magnitude as that of CPT-11, but they were refractory to etoposide and taxol. In conclusion, CPT-11 demonstrated significant activity against pPNET and neuroblastoma xenografts. Further clinical development of CPT-11 in paediatric oncology is warranted.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumorsCancer Chemotherapy and Pharmacology, 1995
- Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical TrialsJNCI: Journal of the National Cancer Institute, 1994
- Effects of CPT‐11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno‐transplanted neuroblastomaMedical and Pediatric Oncology, 1994
- Mechanisms of Topoisomerase I Inhibition by Anticancer Drugs1994
- Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumoursNature, 1992
- P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for NeuroblastomaNew England Journal of Medicine, 1991
- Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835International Journal of Cancer, 1989
- Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1Cancer, 1989
- Preclinical phase II studies in human tumor lines: A European multicenter studyEuropean Journal of Cancer and Clinical Oncology, 1988
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984